Oncolytics Biotech (ONCY) Stock News
$ONCY · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Oncolytics Biotech (ONCY) in the past 30 days, 1 of it high impact. BORSA’s news read on ONCY is bullish at 60/100, −1 over 24 hours, based on 1 company event over the past 30 days. Oncolytics Biotech’s next earnings report is scheduled for Wednesday, Nov 11.
The wire on $ONCY
newest first · updated · direct subject stories onlyOncolytics Biotech Reports Accelerating Enrollment in REO 033 Colorectal Cancer Study
Nearly all planned clinical sites for Part A of the randomized REO 033 study are now activated. Multiple patients are on study. The company expects to report interim data by year-end 2026. FDA alignment supports a potential accelerated approval path based on objective response rate.
bullish 80 · impact 70